C ardiac resynchronization therapy with or without defibrillator (CRT-D/CRT) has been shown to reduce the morbidity and mortality in patients with mild and severe heart failure (HF) in several randomized clinical trials. [1] [2] [3] [4] [5] [6] In patients with mild HF, this benefit was restricted to patients with left bundle brunch block (LBBB). 7 
Clinical Perspective on p 926
Low systolic blood pressure (SBP) is a well-established independent predictor of morbidity and mortality, despite medical therapy in patients with either relatively reduced or preserved systolic HF. 8 We have previously shown that in patients with ischemic left ventricular (LV) dysfunction, there is an inverse correlation between SBP and sudden cardiac mortality, which is translated to a greater risk reduction in mortality with implantable cardioverter defibrillator (ICD) when compared with optimal medical therapy in patients with low SBP.
However, data on risk stratification according to SBP and the implications of SBP change on long-term outcomes are lacking. Therefore, we hypothesized that treatment with CRT-D would provide incremental clinical benefit in higher-risk HF patients with lower baseline SBP values.
Accordingly, in this Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) long-term follow-up substudy, we aimed to evaluate (1) long-term differences in clinical outcome of HF or death by baseline SBP in patients who were treated with ICD-only therapy, (2) long-term CRT-D benefit when compared with ICD-only by baseline SBP, and (3) whether changes in SBP have implications on long-term outcomes, in LBBB patients.
Methods

Study Population
In the MADIT-CRT study, 1820 patients with LVEF <30%, QRS duration of at least 130 ms, and either ischemic cardiomyopathy and New York Heart Association class I-II symptoms or non-ischemic cardiomyopathy class and New York Heart Association class II were randomly assigned to CRT-D or ICD treatment arms. The protocol and results of the study have been detailed previously. 1, 11 Patients from both treatment arms received optimal medical therapy for HF consisting of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers/angiotensin II inhibitors, β-blockers, and statins. Exclusion criteria included New York Heart Association class III or IV symptoms, coronary artery bypass graft surgery, percutaneous coronary intervention, or myocardial infarction within 90 days before enrollment; second-or third-degree heart block; chronic atrial fibrillation; and comorbidities, such as uremia (blood urea nitrogen, >70 mg/dL or creatinine >3.0 mg/dL) and liver failure.
In the present study, we included MADIT-CRT patients with available baseline SBP and LBBB ECG pattern at baseline because it was previously shown that the benefit of CRT-D is restricted to patients with LBBB pattern. 6, 7 Consequently, the present study population comprised 1267 LBBB patients, 69% of the total 1820 original study patients.
Follow-Up
MADIT-CRT was performed from December 22, 2004, to June 22, 2009. After publication of the primary results, 1 post-trial follow-up was conducted for all surviving study participants (n=1691) until September 10, 2010 (phase I of the extended follow-up). After September 10, 2010, ongoing patient follow-up data were obtained on 854 patients enrolled at both US and non-US enrolling centers. The Heart Research Follow-up Program at the University of Rochester Medical Center in Rochester, NY, coordinated follow-up data collection as requested by the Food and Drug Administration for 407 patients from the 48 US centers that agreed to participate. Follow-up data were collected for 447 patients from the 23 non-US centers that agreed to participate and coordinated by the Israeli Association for Cardiovascular Trials at Sheba Medical Center, Ramat Gan, Israel. Both phases of the post-trial follow-up were approved by the institutional review board of each participating center and by the Rochester University institutional review committee; all patients provided written informed consent. Post-trial clinical and adverse events were obtained at 6-month intervals during follow-up.
Definitions and End Points
Patients with an LBBB and an implanted CRT-D or an ICD device were divided into 5 subgroups based on the baseline SBP quintile (<110 mm Hg; ≥110 and ≤118 mm Hg; >118 and ≤ 125 mm Hg; >125 and ≤136 mm Hg; and >136 mm Hg). To ease the interpretation, the patients were then grouped into 3 SBP categories: low SBP (first quintile, <110 mm Hg), medium SBP (quintiles 2-4, ≥110 and ≤136 mm Hg), and high SBP (fifth quintile, >136 mm Hg).
The primary end point of the current study was HF admission or death (whichever came first), the secondary end point was death. The effect of CRT-D on SBP was predefined as the change between baseline measurement and 6-month follow-up measurement. The 6-month follow-up was chosen to avoid the influence of changes in medication on outcomes, on the one hand, and to evaluate the effect of CRT-D, on the other.
Statistical Analysis
Baseline clinical characteristics were compared between patients from the 3 SBP groups, using the χ 2 test or Fisher exact test for categorical variables. For purposes of consistency, we used the KruskalWallis test for all continuous variables. Categorical data are presented as frequencies and percentages and continuous variables as medians and corresponding inner quartile ranges. The cumulative probability of long-term primary and secondary end points were displayed according to the Kaplan-Meier method by baseline SBP and by treatment arm within each SBP group, with comparisons of cumulative event rates by the log-rank test.
Multivariate Cox proportional hazards regression analysis was used to assess the effect of SBP on the risk of long-term primary and secondary end points in patients with ICD. The Cox model was adjusted for relevant clinical covariates using best subset regression modeling (age, body mass index, creatinine, LV end-systolic volume, prior congestive heart failure hospitalization, LVEF, New York Heart Association, and white race). This model was then used to assess the effect of CRT-D to reduce the risk of the long-term primary and secondary end points.
Interaction P values and P value for trend were computed and reported between the SBP groups. A landmark analysis was used to assess the effect SBP change at 6 months at long-term HF or death.
All statistical tests were 2 sided; a value of P<0.05 was considered statistically significant. Analyses were performed with SAS software (version 9.4; SAS Institute, Cary, NC).
Results
Among 1267 study patients, 241 (19%) patients had low SBP, 776 (61%) had medium SBP, and 250 (20%) had high SBP. Baseline characteristics are shown in Table 1 . Overall, patients with low SBP were younger. This group had properties of more severe HF including higher frequency of congestive heart failure hospitalizations at >3 months before enrollment, higher rates of diuretics regimen, and lower rates of calcium channel blockers. All groups were equally treated with β-blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. Creatinine and blood urea nitrogen levels were slightly elevated in the low SBP group, and echocardiographic parameters were slightly better at the higher SBP group. The high SBP group was more represented in the CRT-D treatment arm. The baseline characteristics of CRT-D versus ICD arm within each SBP group are shown in Table IA to IC in the Data Supplement . Patients with low SBP from the ICD treatment arm had higher frequency of prior atrial arrhythmias, but lower rates of prior ventricular arrhythmias when compared with CRT-D arm. The characteristics of patients with medium and high SBP were similar between the CRT-D and the ICD groups.
SBP and Outcome in the ICD Treatment Arm
Kaplan-Meier analysis showed that >7 years of follow-up, the cumulative probability of the primary and secondary end point was significantly higher among ICD-only patients who had low SBP at baseline than among those who had medium or high SBP values (Figure 1 
Relation of CRT-D Benefit to SBP
The CRT-D to ICD benefit to reduce the primary end point was shown to be attenuated with the increase of SBP in a univariate Kaplan-Meier analysis (Figure 2A-2C) . Accordingly, in a multivariate Cox proportional hazards regression analysis (Tables 2-3) , the low SBP group (first quintile) had the highest risk reduction of the primary end point with CRT-D versus an ICD-only, whereas patients with medium SBP (quintiles 2-4) had lower reduction and patients with high SBP (fifth quintile) had no reduction at all (P for trend=0.001; P for SBP quintiles [as continuous ordinal variable] by treatment interaction=0.012).
Similar trend was shown when the secondary end point was analyzed. Low SBP was associated with the highest CRT-D versus ICD secondary end point reduction (HR, 0.48; 95% CI, 0.26-0.89; P=0.020), the reduction was attenuated in the medium SBP subgroup (HR, 0.71; 95% CI, 0.49-1.05; P=0.084) and was not evident in the high SBP subgroup (HR, 1.04; 95% CI, 0.48-2.25; P=0.916), P for trend=0.106.
Effect of CRT-D Versus ICD on SBP During Follow-Up
Six months after implantation of CRT-D, only patients with baseline SBP <110 (first quintile) had significant increase in SBP when compared with ICD patients (15% versus 9% accordingly; P=0.004; Figure 3 ). There was a linear inverse relationship between baseline SBP and the 6-month change with either CRT-D or ICD with patients with lower baseline SBP increasing their SBP, whereas patients with high baseline SBP had reduction in their SBP.
Relation of SBP Change to Outcome
The effect of SBP change on outcome was assessed by comparing CRT-D versus ICD benefit in patients who increased Continuous variables: median (interquartile range); categorical variables: n (% of column total). Low SBP, first quintile (<110 mm Hg); medium SBP, quintiles 2-4 (110-136 mm Hg); high SBP, fifth quintile (>136 mm Hg). ACE indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CHF, congestive heart failure; CRT-D, cardiac resynchronization therapy with defibrillator; DBP, diastolic blood pressure; LAV index, left atrial volume indexed by body surface area; LVEDV index, left ventricle end-diastolic volume indexed by body surface area; LVEF, left ventricular ejection fraction; LVESV index, left ventricle end-systolic volume indexed by body surface area; NYHA, New York Heart Association; Prior, >3 months before enrollment; and SBP, systolic blood pressure.
*Donates P value of <0.05 for the comparison between patients from the 3 SBP groups. their SBP to those who failed to increase their SBP at 6 months in a landmark analysis. In the multivariate analysis, patients with increased SBP at 6 months had higher risk reduction in HF or death when compared with patients without SBP increase (HR, 0.39; 95% CI, 0.28-0.54 versus HR, 0.58; 95% CI, 0.43-0.77, respectively), with a trend toward significant CRT-D treatment by SBP interaction (P=0.082).
Discussion
The main finding of this study is that patients with mild HF, LVEF under 30%, QRS longer than 130 ms, and LBBB with low SBP at baseline are at higher risk for the primary end point with ICD therapy alone and gain more benefit with CRT-D than patients with medium and high SBP. This outcome benefit is most probably attributable to SBP elevation with CRT-D. This noninvasive and simple hemodynamic measurement may be used to identify higher risk groups when considering CRT-D implantation, and it might be useful to assess response to CRT-D.
Previous studies have demonstrated an association between low blood pressure and unfavorable clinical outcomes with HF patients. Data from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) registry have shown that SBP<120 was an independent predictor of morbidity and mortality. 8 In the Acute Decompensated Heart Failure National Registry (ADHERE) study, SBP<115 mm Hg was the second Adjusted for age, body mass index, creatinine, left ventricle endsystolic volume indexed by body surface area, prior congestive heart failure hospitalization, white race, New York Heart Association, left ventricular ejection fraction, CRT-D treatment, and SBP quintile×CRT-D treatment interaction. When the quintiles were treated as a linear ordinal categorical variable (Q1, Q2, Q3, Q4, and Q5), P value for SBP by treatment interaction was 0.057. CI indicates confidence interval; CRT-D, cardiac resynchronization therapy with defibrillator; HR, hazard ratio; and SBP, systolic blood pressure. Low vs medium SBP by treatment interaction P value=0.118, low vs high SBP by treatment interaction P value=0.003, medium vs high SBP by treatment interaction P value=0.042. When the quintiles were treated as a linear ordinal categorical variable (low, medium, and high), P value for SBP by treatment interaction was 0.012. CI indicates confidence interval; CRT-D, cardiac resynchronization therapy with defibrillator; HR, hazard ratio; and SBP, systolic blood pressure.
*Adjusted for age, body mass index, creatinine, left ventricle endsystolic volume indexed by body surface area, prior congestive heart failure hospitalization, white race, left ventricular ejection fraction, New York Heart Association, CRT-D treatment, and SBP group×CRT-D treatment interaction. best independent predictor for mortality after renal failure in patients with both preserved and reduced LVEF. 12 In another study, SBP<110 was a predictor for mortality and heart transplant among patients who were considered for heart transplant. 13 A Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II substudy demonstrated the association between low SBP and higher risk of sudden cardiac mortality in patients with ischemic cardiomyopathy and moderate to severe HF on optimal medical treatment and the reduction of risk with ICD. 9 However, in this study, we extended this observations showing that low SBP predicts HF or death and death in ICD-treated mild HF patients with both ischemic and nonischemic cause.
CRT-D is one of the fundamental treatment modalities for patients with mild HF and reduced EF, despite optimal medical therapy, currently indicated for those with prolonged QRS and LBBB morphology and seems to be less promising for non-LBBB morphology. 14, 15 Previous risk stratifications were made in an era where the importance of QRS morphology was not fairly appreciated; therefore, it is important to identify higher risk patients within the LBBB group. In the current study, we have shown that CRT-D versus ICD benefit was inversely related to SBP with a significant SBP by treatment interaction, suggesting that CRT-D benefit is attenuated with high SBP.
The mechanism by which low SBP patients gain extended outcome benefit with CRT is thought to be related to SBP elevation secondary to the myocardial contractility improvement. It should be noted that there was no difference in the use of HF medications at baseline, and the relationship between CRT-D benefit and SBP persisted after adjustment to concurrent therapies with BP-lowering medications. In a systemic review of previous studies, CRT was related to mild elevation of SBP, but none of these studies had shown the relation to baseline SBP. 10 In this study, we show that the change in SBP is inversely related to the baseline measurement, and that only the low SBP group had significant elevation with CRT-D over ICD (15% versus 9%), whereas the upper SBP quintiles had SBP reduction, with a linear trend. We also conducted a landmark analysis that showed that patients who had SBP elevation had trend toward higher risk reduction of HF or death with CRT-D versus ICD than patients with unchanged or declined SBP (P for CRT-D treatment by SBP change interaction=0.082).
Limitations
This is a retrospective, nonrandomized post hoc study. Although multivariate analysis showed superior benefit with CRT-D in patients with lower SBP when adjusting for many confounders, it was not a prospective trial and possible unmeasured confounders may have biased the results; therefore, our results should be interpreted as hypothesis generating. Furthermore, we have only included patients with LBBB morphology because CRT-D benefit was shown to be limited to this subgroup, thus excluded about one third of the original study patients. It should be noted that LBBB was not a prespecified variable in the MADIT-CRT trial. Finally, subgroup analyses are underpowered, particularly when moving onto subgroups of subgroups and caution in the interpretation of the subgroup interactions is needed because of multiple testing.
Conclusions
In patients with mild HF, prolonged QRS, and LBBB, low SBP is related to higher risk of mortality or HF with ICD therapy alone and greater risk reduction of HF or death with CRT-D, accompanied by an increase in SBP during follow-up.
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